Comment on topical lomustine therapy for psoriasis.
D001830:Body Surface Area; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003864:Depression, Chemical; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D004355:Drug Stability; D006801:Humans; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014677:Pharmaceutical Vehicles; D010859:Pigmentation Disorders / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy*; D013997:Time Factors
D003510:Cyclohexanes; D003879:Dermatologic Agents; D009607:Nitrosourea Compounds; D014677:Pharmaceutical Vehicles